For the first time, at our knowledge, we identified and proposed blood circulating immunosuppressive CD137+Tregs and LOX-1+PMN-MDSCs as immune biomarkers of resistance to ICIs in (R/M) HNSCC patients. This evidence concerns the gene TNFRSF9 and head and neck squamous cell carcinoma.